logo-loader
view4D pharma plc

4d pharma's Duncan Peyton outlines crucial next stage for its cancer trial

4d pharma plc's (LON:DDDD) Duncan Peyton updates Proactive's Andrew Scott following the news the next stage of its cancer clinical study is underway with four new sites added in the US to accelerate patient recruitment. Up to 30 people per tumour type will participate in Part B of the company’s phase I/II trial to assess its live biotherapeutic, MRx0518, in combination with immune checkpoint inhibitor Keytruda.

Quick facts: 4D pharma plc

Price: 50.8363 GBX

LSE:DDDD
Market: LSE
Market Cap: £66.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

4d Pharma's Duncan Peyton updates as enrolment begins for Phase II COVID-19...

4d Pharma's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott its phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients in hospital with COVID-19 is now open to enrolment. Dosing of the first patients should begin shortly and Peyton says that as MRx-4DP0004 is a...

on 2/7/20

2 min read